Aplagon

Executive Summary

Aplagon is a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics for thromboinflammatory diseases, a major driver of cardiovascular morbidity and mortality worldwide. The company's lead asset, APAC, is a unique triple-action molecule designed to target vascular injury by modulating coagulation, inflammation, and endothelial function simultaneously. Thromboinflammation underlies conditions such as acute coronary syndrome, stroke, and peripheral artery disease, affecting hundreds of millions globally. Aplagon's approach offers potential advantages over existing therapies that address only single pathways, aiming to reduce thrombotic events without increasing bleeding risk. Based in Helsinki, Finland, Aplagon was founded in 2018 and has advanced APAC into Phase 2 clinical development, leveraging its proprietary platform to address significant unmet needs in cardiovascular medicine. APAC is currently being evaluated in a Phase 2 trial for thromboinflammatory indications, with a focus on demonstrating proof-of-concept in patients with vascular injury. The company's strategy includes generating robust clinical data to support further development and potential partnerships with larger pharmaceutical companies. Given the global burden of cardiovascular diseases and the lack of effective targeted therapies for thromboinflammation, successful development of APAC could address a substantial market opportunity. Aplagon's near-term priorities include completing enrollment and reporting top-line data from its ongoing trial, as well as securing additional funding or collaborations to advance the asset toward pivotal studies and eventual commercialization.

Upcoming Catalysts (preview)

• H2 2026Phase 2 top-line data readout for APAC40% success
• 2027Partnership or licensing deal30% success
• 2026Series B or follow-on financing round60% success